ORIGINAL INVESTIGATION Asymmetric dimethylargin

Full list of author information is available at the end of the articleEndothelial dysfunction, a predecessor of atherosclerotic plaques and adverse cardiovascular (CV) events, is largely mediated by depressed bioavailability of nitric oxide (NO) [1]. Biochemical markers of endothelial activation [2-4] and impaired endothelium-dependent vasodilation [5] have also been identified as predictors of new-onset type 2 diabetes a major precursor of non-insulin-dependent diabetes [6-9] and coronary atherosclerosis progression [10,11]. The endogenous inhibitor of NO formation, asymmetric dimethylarginine (ADMA), is associated with endothelial dysfunction and adverse outcome predictor including all-cause mortality and CV events in patients with coronary artery disease (CAD) and in the general population [12]. Mittermayer et al. [13] identified elevated ADMA but not IR as an independent predictor for deterioration in glucos